Table 4.

Korean FDA approval and reimbursement by the Korean Health Insurance System for pulmonary arterial hypertension-targeted therapeutics

Mechanism of action	Name of drug	Route of delivery	Korean FDA approval	Reimbursed by NHIS	Reimbursed for NYHA functional classes
					II	III	IV
ERA	Ambrisentan	PO	○	○	×	○	×
	Bosentan	PO	○	○	×	○	○
	Macitentan	PO	○	○	×	○	×
PDE-5 inhibitor	Sildenafil	PO	○	○	○	○	×
	Tadalafil	PO	×	×	×	×	×
	Vardenafil	PO	×	×	×	×	×
Prostacyclin analogues	Epoprostenol	IV	×	×	×	×	×
	Iloprost	INH	○	○	×	○	○
		IV	×	×	×	×	×
	Treprostinil	SC	○	○	×	○	○
		INH	×	×	×	×	×
		IV	○	○	×	○	○
		PO	×	×	×	×	×
	Beraprost	PO	○	○	No clear criteria
	Selexipag	PO	○	○	×	○	×
sGC stimulator	Riociguat	PO	○	×	×	×	×

FDA, Food and Drug Administration; NHIS, National Health Insurance Service; NYHA, New York Heart Association; ERA, endothelin receptor antagonist; PO, per oral; PDE-5, phosphodiesterase 5; IV, intravenous; INH, inhaled; SC, subcutaneous; sGC, soluble guanylyl cyclase.